SIM 0802
Alternative Names: SIM-0802Latest Information Update: 16 Nov 2023
At a glance
- Originator Unknown
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Disks large homolog 4 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Stroke
Most Recent Events
- 01 Nov 2023 SIM 0802 is available for licensing as of 01 Nov 2023. https://en.simcere.com/kfhz/kfhz.aspx
- 01 Nov 2023 Preclinical trials in Stroke in China (unspecified route) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)
- 31 Dec 2022 Phase-I clinical trials in Autoimmune disorders (unspecified route) prior to December 2022